YSB issued a total of 1.3866 million shares according to the stock purchase agreement.

YSB (09885) announced that, due to the completion of the prerequisite conditions by Kangqiao and in accordance with the share purchase agreement, a total of 1.3866 million consideration shares will be issued at a price of 12 Hong Kong dollars per share on April 11, 2025, as part of the completion consideration.

Sina Hong Kong StockApr 14 08:42

YSB (09885.HK) awarded 0.98 million shares as bonus shares.

Gelonghui, April 3rd丨YSB (09885.HK) announced that on April 3, 2025, the company granted 0.98 million shares of awarded stock to the participants in the 2023 stock incentive plan, involving 0.98 million new shares, accounting for approximately 0.14% of the total issued shares as of the announcement date.

Gelonghui FinanceApr 3 21:11

The Traditional Chinese Medicine industry is ushering in a bullish trend, and YSB is expected to benefit from a new round of policy dividends.

On March 21, 2023, Gelonghui announced that on March 20, the State Council issued "Opinions on Improving the Quality of Traditional Chinese Medicine and Promoting the High-Quality Development of the Traditional Chinese Medicine Industry," which clearly outlines core tasks such as advancing the full chain quality traceability, Asia Vets transformation, and technology innovation, bringing structural upgrade opportunities to the Traditional Chinese Medicine industry. As a digital pharmaceutical platform, YSB, leveraging its forward-looking layout and technological innovation advantages, is expected to seize the opportunity in the industrial upgrade. Since 2021, YSB has keenly perceived the upgrade trend in the Traditional Chinese Medicine industry and has taken the lead in initiating a full Industry Chain layout. In response to the pain points of non-standard Traditional Chinese Medicine materials, the company has innovatively developed 271 golden standard specifications, covering Astragalus and other materials.

Gelonghui FinanceMar 21 08:28

YSB (9885.HK): Strategic turnaround to profitability in 2024 with "fast turnover + strong cash flow + high dividends".

Event: The company announced its annual performance for 2024, achieving revenue of 17.904 billion yuan (yoy +5%), adjusted net income reached 0.157 billion yuan (yoy +20%), and net income attributable to shareholders is 0.

Cinda SecuritiesMar 20 16:42

The new forces in medicine under the surge of AI: Decoding the intelligent secrets behind YSB (9885.HK) performance turnaround.

Nowadays, AI unquestionably stands at the forefront, becoming the absolute main line chased by capital. The "AI + Medical" integration is seen by the market as the most explosive strategic high ground due to its potential to reconstruct traditional diagnostic and treatment models. As the AI wave sweeps through the healthcare industry, YSB (9885.HK), China’s largest outpatient pharmaceutical digital comprehensive service platform, recently presented its performance report for 2024, providing vivid proof of this technological revolution. The Earnings Reports show that the company's annual revenue grew by 5.5% year-on-year to 17.904 billion yuan, with net income exceeding 30.01 million yuan, achieving a full positive turnaround for the first time, with adjusted net income reaching.

Gelonghui FinanceMar 20 08:47

YSB To Go Ex-Dividend On May 23rd, 2025 With 0.081 HKD Dividend Per Share

March 18th (Beijing Time) - $YSB(09885.HK)$ is trading ex-dividend on May 23rd, 2025.Shareholders of record on May 26th, 2025 will receive 0.08131 HKD dividend per share on June 18th, 2025. The ex-

Futu NewsMar 18 17:15